At a glance
ClinicalIndex Comparison RecordN/ACompleted· 56 enrolled
Drug / intervention
Levomilnacipran +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Novel Medication as a Potential Smoking Cessation Aid
In Brief
A clinical study evaluating Levomilnacipran and Placebo for Tobacco Use Disorder. Completed, enrolled 56 participants across 1 site.
Detailed Summary
The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use Disorder
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartJan 2015
Primary CompletionMay 2017
TodayJul 2026
First PostedOct 15, 2014
Enrollment StartJan 1, 2015
Primary CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.7 years ago
Interventions
Levomilnaciprandrug
Placebodrug